Personalised antiemetic prophylaxis with NEPA for patients at high risk of chemotherapy-induced nausea and vomiting receiving moderately emetogenic chemotherapy: results from the randomised, multinational MyRisk trial

When individual risk factors are considered before MEC, a three-drug regimen including NEPA provides superior CINV prevention across multiple cycles compared with the standard two-drug approach. These findings underscore the value of personalised risk-adapted antiemetic strategies and have practice-changing potential for optimising antiemetic control.

Authors

Institutions

Publication Details

Journal
Annals of Oncology
Published
2025-10-17
DOI
https://doi.org/10.1016/j.annonc.2025.10.017
Citations
2
Primary Topic
Nausea and vomiting management
Type
article
Field-Weighted Citation Impact
4.01

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Personalised antiemetic prophylaxis with NEPA for patients at high risk of chemotherapy-induced nausea and vomiting receiving moderately emetogenic chemotherapy: results from the randomised, multinational MyRisk trial

E.J. Roeland, A. Alonzi, Silvia Olivari Tilola, Daniel C. Christoph et al.
2 citations
Annals of Oncology
Nausea and vomiting management
4.01
article

Personalised antiemetic prophylaxis with NEPA for patients at high risk of chemotherapy-induced nausea and vomiting receiving moderately emetogenic chemotherapy: results from the randomised, multinational MyRisk trial

E.J. Roeland, A. Alonzi, Silvia Olivari Tilola, Daniel C. Christoph, Alex Molassiotis, M. Majem, E. Tomlins, Matti Aapro, M. Karthaus, Martina Zimovjanová, Karin Jordan, Xun‐Xi Lu, K. Syrigos, Pilar Alfonso, D. Mavroudis, Lee S. Schwartzberg, E Vazquez, Tomáš Büchler, V. Stimamiglio, Zhe Zhou, Ying Cheng, George Dranitsaris, E. Bonizzoni
article en
2 citations

Abstract

When individual risk factors are considered before MEC, a three-drug regimen including NEPA provides superior CINV prevention across multiple cycles compared with the standard two-drug approach. These findings underscore the value of personalised risk-adapted antiemetic strategies and have practice-changing potential for optimising antiemetic control.

Annals of OncologyVol. 37(2)
Oregon Health & Science University (US), University of Derby (GB), Heidelberg University (DE), Hospital de Sant Pau (ES), University Hospital Heidelberg (DE), Renown Health (US), Shanghai Chest Hospital (CN), Hospital General Universitario Gregorio Marañón (ES), Clinique de Genolier (CH), Helsinn (Switzerland) (CH), Royal Marsden Hospital (GB), Derby College (GB), Augmentium Pharma Consulting (Canada) (CA), University Hospital of Heraklion (GR), Complexo Hospitalario Universitario A Coruña (ES), Thomayer University Hospital (CZ), Obstetrics and Gynecology Hospital of Fudan University (CN), München Klinik Neuperlach (DE), Evangelisches Krankenhaus Königin Elisabeth Herzberge (DE), Klinikum Ernst von Bergmann (DE), General University Hospital in Prague (CZ), Sotiria General Hospital (GR)
Helsinn
Openalex Percentile: Top 6%
Nausea and vomiting management
4.01
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.